DUBLIN--(BUSINESS WIRE)--The "Mammalian Polyclonal IgG Antibody Market by Type, by Product, by Application, by End-user, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
The mammalian polyclonal IgG antibody market size is estimated to be USD 1,347.4 million in 2022 and is expected to witness a CAGR of 5.28% during the forecast period 2023-2033.
Increasing investments by biotechnology and pharmaceutical companies for technological advancement for antibody production and growing prevalence of chronic diseases including cancer are some of the factors contributing to the market growth. Furthermore, growing prevalence of standard laboratory tests, government investment, acceleration in institutional and academic research, and affordability of supporting equipment and technology are other factors supporting the market growth.
However, stringent regulations related to the approval and use of biomarkers and lack of awareness about the use of products is expected to hinder the growth.
Growing prevalence of standard laboratory tests such as microarray assays, western blot analysis, immunohistochemical, and cell imaging is predicted to propel the mammalian polyclonal IgG antibody market growth during the forecast period. For instance, GenScript offers specialized polyclonal antibodies that are appropriate for a range of tests such as sandwich ELISA, Western Blot, CHiP, Immunoprecipitation, IF, IHC, and Flow Cytometry.
Segmentation
By Type
The market is categorized into rabbit, mouse, horse, and goat. In 2022, the mouse segment accounted for the highest revenue share due to the predominant use of these animals for polyclonal antibody production. The immune systems of mice and humans are similar, and the development of the egg and sperm in mice is analogous to that in humans. This genetic semblance helps researchers reduce the variability. Mice are economically advantageous and simple to breed.
For instance, mouse polyclonal antibodies are available from Bio X Cell and cost anywhere between USD 159 for 1 mg and USD 4,155 for 100 mg. These price ranges are distinct for academic and non-profit organizations.
On the other hand, the rabbit segment is anticipated to witness the fastest CAGR during the forecast period due to their high specificity, increased identification during disease diagnosis is made possible by rabbit antibodies' better immune response to small epitopes. The huge diversity of rabbit high-affinity antibodies makes it easier to find immunoglobulins with a wide range of applications, including immunohistochemistry, ELISA, Western Blotting, immunocytochemistry, and others.
For instance, in the U.K., as of January 2023, rabbits were utilised in approximately 2.5% of all scientific endeavours, with the majority of these endeavours being antibody research, including production, diagnostics, and analytics. Hence, it is predicted to fuel the segment growth.
By Product
The market is segmented into metabolic markers, cardiac markers, and renal markers. In the global market, the metabolic markers segment accounted for the largest revenue share in 2022 owing to the increasing use of metabolic biomarkers for the diagnosis of diabetes is anticipated to propel segment growth. For instance, according to projections from the World Diabetes Association, there will be more than 537 million cases of diabetes worldwide in 2021. 90% of those with diabetes have type II, which is the most prevalent form of the disease. Rising cancer incidence rates around the globe are also anticipated to fuel the segment's growth in the upcoming years. The study took into account autoimmune and cancer-related biomarkers.
Additionally, the cardiac markers segment is accounted to grow at fastest CAGR during the forecast period due to the rising prevalence of cardiovascular diseases (CVDs) due to poor eating patterns, inactive lifestyles, and a sedentary way of life. For instance, in 2020, CVDs accounted for 19.1 million deaths globally.
The emerging nations of Eastern Europe, North Africa, and Central Asia recorded the highest incidence rates. With a distribution wide network many nations, including India, Australia, China, Belgium, Germany, Israel, India, and Hong Kong, Life Diagnostics is a regional competitor in the United States. Hence, the increasing distribution network of market players is expected to boost the growth of the market.
By Application
The market is segmented into western blotting, immunoturbidometry, ELISA, immunocytochemistry, immunoelectrophoresis, antibody identification, and immunohistochemistry. In 2022, the ELISA segment accounted for the largest revenue share owing to its predominant use in antibody-related tests. Its accuracy in diagnosing disorders including AIDS, Lyme disease, syphilis, pernicious anaemia, and viral infections makes it the most widely used test. In the near future, it is anticipated that immunohistochemistry, which is used to detect tumours, would contribute significantly to income. This is mostly due to its increased specificity, which facilitates the detection of structural variations frequently found in tumour cells. Growth in the industry is also projected to be fuelled by increasing usage and equipment advances.
For instance, in February 2021, the Agilent Technologies Inc. has introduced the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit, which is intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. Additionally, the western blotting segment is anticipated to have the fastest CAGR over the projected period owing to its sensitivity and specificity.
Western blotting enables illness identification with a minimal number of antibodies, significantly lowering lab costs. Another important aspect driving this test's rising demand is its protein selectivity. The advantages of Western blotting for protein detection, including its speed, low cost, ease of use, increased sensitivity, and compatibility with immunodetection, help the segment maintain a bigger market share.
By End-user
The market is segmented into diagnostic centres, academic and research centres, hospitals, and pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment accounted for the highest revenue share during the forecast period. As the development of a coronavirus antibody provides a company an advantage in setting the standard for the industry, the global pandemic can be a major motivator for companies. For instance, to help with the creation of an antibody drug for COVID-19, GlaxoSmithKline spent USD 250 million in Vir Biotechnologies in 2020. Additionally, the academic and research centres segment is predicted to witness the fastest CAGR during the forecast period due to the increased number of research activities on personalized medicine and improving drug efficacy. For instance, in April 2020, The University of Arizona Health Sciences partnered with the State of Arizona to conduct an antibody blood test for COVID-19. The State offered monetary assistance of USD 3.5 million to the university. Hence, increasing demand for mammalian polyclonal IgG antibodies is anticipated to boost the market growth.
Regional Markets
In 2022, North America region accounted for the highest revenue in the mammalian polyclonal IgG antibody market during the forecast period due to the presence of well-equipped research facilities and leading companies producing antibodies in the region. Rapid technological adoption and an emphasis on clinical research are anticipated to fuel regional growth. The usage of polyclonal antibody methods has increased in the US due to favourable reimbursement regulations. Government agencies like the CDC are present which has helped the regional market to dominate. Increasing R&D efforts and public awareness are two major drivers of growth in this industry.
Key Topics Covered:
1. Research Methodology
2. Introduction: Mammalian Polyclonal IgG Antibody
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Mammalian Polyclonal IgG Antibody Market
7. Market Analysis by Type
8. Market Analysis by Product
9. Market Analysis by Application
10. Market Analysis by End User
10. Regional Market Analysis
11. North American Mammalian Polyclonal IgG Antibody Market
11. Europe Mammalian Polyclonal IgG Antibody Market
12. Asia PacificMammalian Polyclonal IgG Antibody Market
13. Latin America Mammalian Polyclonal IgG Antibody Market
14. MEAMammalian Polyclonal IgG Antibody Market
15. Competitor Analysis
16. Company Profiles
17. Conclusion & Recommendations
A selection of companies mentioned in this report includes
- Novartis AG
- Abcam plc.
- F. Hoffmann-La Roche Ltd.
- Cell Signaling Technologies
- Bio-Rad Laboratories
- Merck KGaA
- Thermo Fisher Scientific
- Geno Technology Inc.
- Phoenix Pharmaceuticals
- Stemcell Technologies Inc.
For more information about this report visit https://www.researchandmarkets.com/r/d6y2hu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
